Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Shock"
Show Display Options
Rank Status Study
1 Recruiting Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Recurrent Glioblastoma;   Recurrent Adult Brain Tumor;   Gliosarcoma
Interventions: Biological: HSPPC-96;   Drug: bevacizumab

Study has passed its completion date and status has not been verified in more than two years.